Phase 3 Data Support ENTYVIO® (vedolizumab) for Pediatric Moderate to Severe Ulcerative Colitis
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis Takeda today announced positive data from the pivotal…
Dock Health Deploys Workflow Productivity Platform at Mayo Clinic
Dock Health Introduces Its Productivity Platform at Mayo Clinic to Modernize Operational Workflows Dock Health today announced that its productivity platformhas been implemented at Mayo Clinic to automate and optimize operational workflows in its cardiovascular,…
NexEos Bio Secures FDA Green Light to Progress NTX-1024 into Phase II/III Clinical Development
NexEos Bio Announces FDA Clearance of IND Application to Proceed to Phase II/III Trial of NTX-1024 in Vernal Keratoconjunctivitis NexEos Bio Vision Health a clinical-stage biopharmaceutical company developing novel therapies…
Case Study Shows CyPath® Lung Reduces Diagnostic Burden in At-Risk Patients
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer bioAffinity Technologies, Inc. a biotechnology company advancing noninvasive diagnostics for…
Unified Women’s Healthcare Addresses Growing Demand for Menopause Care
Unified Women’s Healthcare Responds to Rising Demand for Menopause Care Unified Women’s Healthcare (Unified), in partnership with its OBGYN affiliates, is expanding access to perimenopause and menopause care nationwide through Unified for…
ImmunityBio Expands EU Access to ANKTIVA® with New Distribution Deal
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch ImmunityBio, Inc. a commercial-stage immunotherapy company, today announced a partnership with Accord…
BioTalent Canada Launches Workplace Harassment Prevention Training
BioTalent Canada Launches Training to Help Employers Prevent and Respond to Workplace Sexual Harassment BioTalent Canada is launching online training courses to empower managers and hiring leaders to confidently prevent…
bit.bio Expands Global Access to Human Cells with New Pricing and Hub
bit.bio Accelerates Global Access to Human Cells with New Pricing Model and Distribution Hub Following a record Q4 in sales volume and the successful closing of $50 million in new…
Pilatus Biosciences Secures FDA Fast Track for PLT012 in Liver Cancer
Pilatus Biosciences Receives FDA Fast Track Designation for Metabolic Checkpoint Inhibitor PLT012 in Hepatocellular Carcinoma Pilatus Biosciences Inc., a biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal…
Enveric Biosciences Shares EB-003 BRET Assay Data
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data Enveric Biosciences a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new mechanistic data…
Positive Interim Results Announced for YOLT-202 in Alpha-1 Antitrypsin Deficiency
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced…
Henry Schein One Launches Image Verify to Improve Claims Accuracy
Henry Schein One Launches Image Verify, Another Transformative Step Towards Achieving the Cleanest Claims in the Industry Henry Schein One, the market leader in dental practice management systems, today announced…